Look back at pharma news in the week to May 7, 2021

9 May 2021

By Barbara Obstoj-Cardwell. Editor

Last week saw Novartis’ Sandoz unit on Monday announce it is progressing the development of biosimilars to Bayer and Regeneron’s blockbuster ophthalmic drug Eylea. Also of note, the US medicine cost watchdog, the Institute for Clinical and Economic Review (ICER), issued a draft report questioning the benefit/risk of Biogen and Eisai’s Alzheimer’s disease candidate aducanumab. And Roivant Sciences entered into a $7.3 billion SPAC (special purpose acquisition company) deal with Montes Archimedes to go public. Marking an important new indication for Merck & Co’s Keytruda, the US Food and Drug Administration (FDA) approved the blockbuster drug for the first-line treatment of HER2-positive gastric cancer.

Sandoz Phase III plans for Eylea biosimilar is a win for Regeneron

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK